Ron DeSantis Spent Monday Pushing a $1200 COVID-19 Treatment. Vaccines, of Course, Are Free

2 months ago 41
PR Distribution

Back successful the aboriginal days of the COVID-19 pandemic, Donald Trump, Republican lawakers and Conservative media relentlessly pushed the cause hydroxychloroquine. And contempt their repeated claims astir the drug, it turned retired to beryllium beauteous overmuch useless.

The state present has a large mode to combat COVID-19, vaccines that person proven to beryllium incredibly effective. Still, successful reddish states, vaccinations rates are debased and COVID cases are high.

Ron DeSantis is dealing with yet different monolithic COVID surge successful Florida. And alternatively than relentlessly advising radical to get inoculated, helium is pushing attraction with monoclonal antibodies. And dissimilar the escaped vaccine, this attraction costs astatine slightest $1200.

The Florida politician announced the availability of the cause successful Orlando today. He told reporters, “Early attraction with these monoclonal antibodies, Regeneron and others, person proven to radically trim the accidental that idiosyncratic ends up being hospitalized. And astatine the extremity of the day, reducing infirmary admissions has got to beryllium a apical priority.”

Gov. Ron DeSantis: "Early attraction with these monoclonal antibodies, Regeneron and others, person proven to radically trim the accidental that idiosyncratic ends up being hospitalized. And astatine the extremity of the day, reducing infirmary admissions has got to beryllium a apical priority." https://t.co/RfzPfPILPn

Image

DeSantis besides noted, “The extortion against terrible unwellness is holding, but it is not bringing connected herd immunity. The unvaccinated are inactive overmuch much apt to beryllium admitted to hospitals.”

It seems rather backwards to hold to drawback COVID earlier seeking treatments. And determination are definite to beryllium questions astir who volition beryllium profiting from this newest treatment.

Read Entire Article